3-[4-[1-(4-fluorophenyl)-2-phenyl-but-1-enyl]phenyl]acrylic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-[4-[1-(4-fluorophenyl)-2-phenyl-but-1-enyl]phenyl]acrylic acid
• 英文别名: (E)-3-[4-[(E)-1-(4-fluorophenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid
• 化学式: C₂₅H₂₁FO₂
• 分子量: 372.439
• InChiKey: JJVQXEBKXNEEQV-YGCRUXFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Methyl 3-[4-[1-(4-fluorophenyl)-2-phenyl-but-1-enyl]phenyl]acrylate 以 四氢呋喃 、 甲醇 、 氢氧化钾 为溶剂， 以93%的产率得到3-[4-[1-(4-fluorophenyl)-2-phenyl-but-1-enyl]phenyl]acrylic acid
  参考文献：
  名称：

  Halogenated triphenylethylene derivatives as selective estrogen receptor modulators

  摘要：

  本发明描述了新型卤代三苯乙烯衍生物，或其药学可接受的前药或盐形式，作为选择性雌激素受体调节剂，用于治疗和/或预防乳腺、子宫、卵巢、前列腺和结肠癌、骨质疏松症、心血管疾病和良性增生性疾病，以及制备这些化合物和制药组合物的方法。

  公开号：

  US20020013297A1

文献信息

• Treatment of dyspareunia with topically administered nitroglycerin formulations
  申请人：——

  公开号：US20040044080A1

  公开（公告）日：2004-03-04

  Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 hours following administration. The formulations may contain one or more additional active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such additional agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

  本研究提供了治疗性交困难的方法和制剂。将配制成含有治疗有效量硝化甘油的药物组合物施用到接受治疗者的阴道或外阴部位。首选的制剂是速释制剂，其中制剂中至少 80% 的硝酸甘油在给药后 4 小时内从制剂中释放出来。制剂可含有一种或多种额外的活性剂，例如，也可用于治疗性交困难和/或增强硝酸甘油作用的制剂。此类附加制剂包括血管活性剂，如前列腺素、磷酸二酯酶抑制剂、雄激素，如睾酮、雌激素，如雌二醇，以及雌激素和雄激素受体的选择性调节剂。此外，还提供了一种供患者用于自行服用制剂的试剂盒。
• Pharmaceutical compositions for the treatment of sexual disorders II
  申请人：Mendla Klaus

  公开号：US20050245539A1

  公开（公告）日：2005-11-03

  The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.

  本发明涉及用于治疗性障碍的新型药物组合物及其制备方法。在一个优选的实施方案中，本发明涉及由氟班色林作为一种活性成分与至少一种额外的活性成分组合而成的用于治疗性障碍的药物组合物及其制备方法。
• HALOGENATED TRIPHENYLETHYLENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1268389B1

  公开（公告）日：2004-09-22
• NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：EP1740181A1

  公开（公告）日：2007-01-10
• Pharmaceutical Compositions for the Treatment of Sexual Disorders II
  申请人：Mendla Klaus

  公开号：US20110105519A1

  公开（公告）日：2011-05-05

  The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.